Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors

Cristian Tomasetti, George D. Demetri, Giovanni Parmigiani

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Most patients with advanced gastrointestinal stromal tumors (GIST) develop drug resistance to tyrosine kinase inhibitors (TKIs) within two years of starting therapy, whereas most chronic myeloid leukemia (CML) patients in chronic phase still exhibit disease control after a decade on therapy. This article aims to explain this divergence in long term outcomes. Methods and results: By combining clinical and experimental observations with mathematical formulas we estimate that, in advanced GIST, the genetic changes responsible for resistance are generally already present at disease detection. Conclusion: This result has relevant clinical implications by providing support for the exploration of combination therapies.

Original languageEnglish (US)
Article number152.v1
JournalF1000Research
Volume2
DOIs
StatePublished - Jul 9 2013

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors'. Together they form a unique fingerprint.

Cite this